Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gynecologic 1Endocrine 1

Conditions

Neuroendocrine Tumors 12Carcinoma, Neuroendocrine 8Carcinoma, Non-Small-Cell Lung 4Adrenocortical Carcinoma 4Thyroid Neoplasms 3Lung Neoplasms 3Carcinoid Tumor 3Vulvar Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Small Cell Lung Carcinoma 2Sarcoma 2Pheochromocytoma 2Penile Neoplasms 2Parathyroid Neoplasms 2Paraganglioma 2Ovarian Neoplasms 2Osteosarcoma 2Neurofibrosarcoma 2Mesothelioma 2Melanoma 2Hemangiosarcoma 2Gastro-enteropancreatic neuroendocrine tumor 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Carcinosarcoma 2Carcinoma, Renal Cell 2Carcinoma, Adenoid Cystic 2Adrenal Gland Neoplasms 2

Interventions

Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Female × Nivolumab × Endocrine × Clear all
NCT04969887 2026-02-27

MOST-CIRCUIT

Olivia Newton-John Cancer Research Institute

Phase 2 Active not recruiting
240 enrolled
EndocrineNET

Genital Neoplasms, Female, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡